# Waters (WAT) Q2 2026 earnings

Results filed 2026-08-04 for the quarter ended 2026-07-04. Source page: https://earnings.opennash.com/companies/wat/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1000697/000119312526331413/0001193125-26-331413-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Waters' first full quarter owning BD's biosciences and diagnostics businesses showed mid-single-digit growth there, while a broadening instrument replacement recovery lifted its core analytical business.

Waters completed its first full quarter with the Biosciences and Diagnostic Solutions businesses acquired from BD, and they grew 4% on a comparable basis, faster than management expected. Its core Analytical Sciences business saw instrument and chemistry consumables demand strengthen, with Pharma and Academic & Government customers leading and previously lagging segments returning to growth. Management credits a 180-day plan covering pricing, reagent compliance and share recovery in flow cytometry research products.
Management is steering toward revenue synergies from the acquisition, such as service attachment, e-commerce, cross-selling and new products. It is also pursuing replacement of aging flow cytometry and blood culture instruments, with new launches starting in the second half. The main tension is execution: integration, cost actions and a continued decline in China diagnostics must deliver while the market recovery holds. Management is raising every component of full-year guidance.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenue | $1.645 billion | up 113% from a year ago | GAAP |
| Net (loss) income | $(136) | compared with income of $147 million a year ago | GAAP |
| Diluted EPS | ($1.39) | compared with $2.47 a year ago | GAAP |
| Adjusted EPS | $3.05 | up 3% from $2.95 a year ago | non-GAAP |
| Adjusted gross margin | 54.0% |  | non-GAAP |
| Operating (loss) income | (86) | compared with income of $188 million a year ago | GAAP |
| Adjusted operating margin | 25.0% | compared with 29.1% a year ago | non-GAAP |
| Net cash provided by operating activities | 200 | compared with $41 million a year ago | GAAP |
| Free cash flow (adjusted) | $202 | compared with $159 million a year ago | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Analytical Sciences Division | $669 | up 7% as reported |
| Biosciences Division | $368 | up 3% on a prior year comparable basis |
| Advanced Diagnostics Division | $521 | up 7% on a prior year comparable basis |
| Materials Sciences Division | $87 | up 6% as reported |
| Diagnostic Solutions | $449 | compared with $425 million in the prior year comparable period |
| Clinical Business Unit | $72 | compared with $62 million a year ago |
| ASD instrument revenue | $240 | up 8% in constant currency |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Total reported revenue | third quarter of 2026 | $1.745 billion to $1.762 billion |
| Organic constant currency revenue growth | third quarter of 2026 | 8% to 10% |
| Adjusted EPS | third quarter of 2026 | $3.95 to $4.05 |
| Total reported revenue | full-year 2026 | $6.415 billion to $6.476 billion |
| Organic constant currency revenue growth | full-year 2026 | 7.0% to 9.0% |
| Adjusted EPS | full-year 2026 | $14.45 to $14.65 |

## Key takeaways

1. **BD businesses accelerated under Waters' 180-day plan** Biosciences and Diagnostic Solutions grew 4% on a comparable basis, which management says is a faster-than-expected move to mid-single-digit growth. The plan focuses on urgency, pricing and reagent compliance, and regaining share in flow research products.
2. **Instrument recovery has broadened beyond Pharma** Analytical Sciences instruments grew 8% in constant currency, with chemistry consumables up double digits. Pharma grew 11% and Academic & Government 11%, and previously lagging segments are returning to growth.
3. **New flow cytometry and blood culture products drive replacement** Waters introduced the FACSDiscover A7 spectral cell analyzer and began BACTEC FXI placements. It says 10,000+ of ~25,000 flow cytometry installed-base units have aged, and 12,000+ BACTEC systems are past due for replacement, with the opportunity starting in 2H26.
4. **Revenue synergies are the next phase of integration** Management says the acquisition is moving from operational fixes to a first tranche of revenue synergies. These include service plan attachment, e-commerce, cross-selling and new bioseparations products, with taking flow into pharma QC and MALDI-TOF later.
5. **Full-year guidance raised on broader market strength** Waters raised every component of its 2026 outlook, citing better-than-expected results and strengthening end markets. China microbiology remains a drag, declining 13% though better than expected.

## Questions

**What changed at Waters' newly acquired BD businesses this quarter?** In their first full quarter under Waters, the Biosciences and Diagnostic Solutions businesses grew 4% on a comparable basis, ahead of guidance. Management credits a 180-day plan covering pricing, reagent compliance and regaining flow research share.
**Where is demand coming from in Waters' core analytical business?** Pharma grew 11% in constant currency, driven by instrument replacement, GLP-1s, generics and biologics, and Academic & Government grew 11%. Biotech and CRO spending also improved, and lagging customer segments are returning to growth.
**Which new products is Waters launching?** Waters introduced the FACSDiscover A7 spectral flow cytometry analyzer and began placing the BACTEC FXI blood culture system, launched in 2026. Both target instrument replacement opportunities starting in the second half.
**What are the main competitive or risk factors in diagnostics?** Microbiology in China declined 13%, though better than expected, while microbiology outside China grew 6%. Integration execution and realizing synergies are also flagged as risks.
**How is management positioning Waters for growth beyond 2026?** It points to moving from operational improvements to revenue synergies such as service attachment, e-commerce and cross-selling. It also sees reshoring as a 2027-30 tailwind, with 37 of 76 tracked U.S. expansion sites under construction.

## Slides and investor documents

- [Presentation](https://s205.q4cdn.com/962852172/files/doc_financials/2026/q2/V2/Waters-Q2-2026-Earnings-Presentation.pdf) (Slide deck)
- [Non-GAAP Addendum](https://s205.q4cdn.com/962852172/files/doc_financials/2026/q2/V2/Waters-Q2-2026-Non-GAAP-Recs.pdf) (Document)
- [10-Q](https://d18rn0p25nwr6d.cloudfront.net/CIK-0001000697/cd842528-0fb5-4af0-a796-7383c52a9d9a.pdf) (Document)

